Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,501.24
(
0.77%
)
US TECH 100
28,806.40
(
0.76%
)
Dow Jones
50,063.46
(
0.75%
)
Brent Oil
104.63
(
0.43%
)
Bitcoin
81,440.26
(
0.47%
)
News Focus
News Focus
Post# of 257566
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122982
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: jq1234 post# 106651

Wednesday, 04/25/2012 3:38:22 PM

Wednesday, April 25, 2012 3:38:22 PM

Post# of 257566
Pradaxa—the oral anticoagulant from Boehringer-Ingelheim—is now selling at an annualized rate of more than $1B:

http://online.wsj.com/article/BT-CO-20120424-703015.html

Pradaxa was: approved in the EU for VTE prevention in 2008 (#msg-27956748), approved in the US for AF/stroke prevention in 2010 (#msg-55725156); and approved in the EU for AF/stroke prevention in 2011 (#msg-65889172). (B-I never submitted Pradaxa for approval for VTE prevention in the US.)

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today